FX-68

FX-68 (also known as JMS-FX-68) is a novel, potent, and selective small-molecule antagonist of the chemokine receptor CX3CR1. Developed by Drexel University in collaboration with Alliance Discovery, Kerberos Biopharmaceuticals, and The Wistar Institute, FX-68 targets the CX3CR1-fractalkine (CX3CL1) signaling axis. This pathway is heavily implicated in the metastatic seeding, colonization, and survival of circulating tumor cells (CTCs) in the skeleton and soft tissues. In preclinical models of metastatic breast and prostate cancers, FX-68 has demonstrated the ability to impair the homing of CTCs to target organs, reduce metastatic tumor burden, and enhance the efficacy of chemotherapeutic agents like doxorubicin and docetaxel by prolonging the exposure of cancer cells in the bloodstream.